Company: BDRX
Filing Date: 2025-11-17
Form Type: POS AM
Source: 0001214659-25-016826
Chunk: 38

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-11-17
Form: POS AM
Chunk 38
---
 any time concurrently with or within 30 days after the consummation of the fundamental transaction,
an amount of cash equal to the value of the warrant as determined in accordance with the Black Scholes option pricing model.

Transferability.Each
warrant and all rights thereunder are transferable, in whole or in part, upon surrender of the warrant, together with a written assignment
of the warrant subject to applicable securities laws; provided, however, that the Underwriter Warrants are subject to certain FINRA transfer
restrictions. We do not intend to apply for listing of the warrants on any securities exchange or other trading system.

No Rights as Shareholder Until Exercise.Except as set forth in the warrants, the holders of the warrants do not have any voting rights, dividends or other
rights as a holder of our capital stock until they exercise the warrants.

Series G Warrants and Warrant Agent Warrants

The following is a brief summary of the Series G Warrants and Warrant Agent Warrants, issued in connection with the closing of a warrant inducement transaction in May 2024, and is subject in all respects to the provisions contained in the applicable warrants,which
are filed as exhibits to our Report on Form 6-K dated May 22, 2024. Unless otherwise stated, references to warrants in this subsection include the Series G Warrants and Warrant Agent Warrants. The Series H Warrants issued in the transaction have expired.

Exercisability.
The warrants became exercisable on May 24, 2024. The Series G Warrants and Warrant Agent Warrants
expire five years and three years, respectively, from the initial exercise date. The holder shall deliver the aggregate exercise price
for the Depositary Shares specified in the exercise notice within two trading days following the date of exercise (subject to the ‘cashless
exercise’ arrangements described below).

Cashless Exercise. If, at the time a holder exercises its warrants, a registration statement registering the issuance of the securities
underlying the warrants under the Securities Act is not then effective or available and an exemption from registration under the Securities
Act is not available for the issuance of such shares, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in
whole or in part) the net number of Depositary Shares determined according to a formula set forth in the warrants.

Exercise Price.The exercise price of